PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Smartee Denti-Technology Launches AG KIDS in Malaysia
KUALA LUMPUR, Malaysia , Aug. 25, 2026 /PRNewswire/ -- Smartee Denti-Technology launched Smartee AG KIDS, a craniofacial growth guidance system designed for growing patients, in Malaysia. The launch ...
2026-08-25T    Health Care/Hospital 
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
TAIPEI , Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
SEOUL, South Korea , Aug. 25, 2026 /PRNewswire/ -- Classys Inc. (KOSDAQ: 214150) expects device sales worldwide to surpass 50,000 units this year. ...
2026-08-25T    Computer/Electronics   Cosmetics & Personal Care   Health Care/Hospital   Medical Equipment 
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU , Aug. 25, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing ...
2026-08-25T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Thailand's Elite Business Leaders Forge Lasting Legacies at Asia Pacific Enterprise Awards 2026
BANGKOK , Aug. 25, 2026 /PRNewswire/ -- Thailand's elite business leaders and outstanding enterprises have been recognized for forging lasting legacies of excellence, innovation, and resilience at the ...
2026-08-25T    Banking/Financial Service   Beverages   Food/Beverages   Health Care/Hospital 
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG , Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited (" Antengene ", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company ...
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Dimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound Care
NEW YORK , Aug. 25, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with ...
2026-08-25T    Health Care/Hospital   Household/Consumer/Cosmetics   Medical Equipment 
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER [1] basis (41.5% growth on a CER [2] basis) Gross profit grew by 40.6% period-over-period, ...
2026-08-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth
SUZHOU, China , Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, ...
2026-08-24T    Biotechnology   Health Care/Hospital   Medical Equipment 
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
Development of Leptin receptor-based technology and hybrid LNP platform Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential ...
2026-08-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.